FDA’s Top-Four Tablet Scoring Concerns To Get Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
The Advisory Committee for Pharmaceutical Science and Clinical Pharmacology will vote on some aspects of FDA’s draft scoring guidance, potentially giving generic industry a clue of future agency actions.